85 related articles for article (PubMed ID: 19078906)
1. Contaminants in heparins continue to be unfolded.
Fareed J; Ahluwalia M; Wahi R; Ramaccioti E; Hoppensteadt D; Bick RL
Int Angiol; 2008 Dec; 27(6):457-61. PubMed ID: 19078906
[No Abstract] [Full Text] [Related]
2. Contaminants in heparins: are all facts known?
Fareed J; Hoppensteadt DA; Ramacciotti E; Hull RD
Clin Appl Thromb Hemost; 2010 Jun; 16(3):242-3. PubMed ID: 20547552
[No Abstract] [Full Text] [Related]
3. [Artificial polysaccharide in contaminated heparin. Acute hypersensitivity reactions explained--but how could it happen?].
Lindahl U
Lakartidningen; 2008 Sep 24-30; 105(39):2660-1. PubMed ID: 18846871
[No Abstract] [Full Text] [Related]
4. New and generic anticoagulants and biosimilars: safety considerations.
Kalodiki E; Fareed J
Clin Appl Thromb Hemost; 2011 Apr; 17(2):136-9. PubMed ID: 21159711
[TBL] [Abstract][Full Text] [Related]
5. Contaminated heparin-affected patient plasmas are associated with activated contact systems.
Yi Qian ; Jing Pan ; Xiaodong Zhou ; Weiser P; Hong Lu ; Beck AM; Shih FF; Lijuan Zhang
Clin Appl Thromb Hemost; 2010 Jun; 16(3):261-5. PubMed ID: 20547554
[No Abstract] [Full Text] [Related]
6. Contaminated heparin.
Kakkar AK; Bonnefoi M
N Engl J Med; 2008 Sep; 359(12):1292-3; author reply 1293. PubMed ID: 18810795
[No Abstract] [Full Text] [Related]
7. Analysis of cytokine secretion from lymphocytes of patients with hypersensitivity reactions to contaminated heparins.
Martin M; Ott H; Merk HF; Sachs B
Br J Dermatol; 2011 Jan; 164(1):68-75. PubMed ID: 20854434
[TBL] [Abstract][Full Text] [Related]
8. [Anaphylactoid reactions associated with contaminated heparin from China].
Montpas N; Désormeaux A; Keire D; Adam A
Ann Pharm Fr; 2011 Sep; 69(5):258-64. PubMed ID: 21924126
[TBL] [Abstract][Full Text] [Related]
9. Contaminated heparin preparations, severe adverse events and the contact system.
Ramacciotti E; Wahi R; Messmore HL
Clin Appl Thromb Hemost; 2008 Oct; 14(4):489-91. PubMed ID: 18815138
[No Abstract] [Full Text] [Related]
10. Contaminated heparin.
Greinacher A; Warkentin TE
N Engl J Med; 2008 Sep; 359(12):1291-2; author reply 1293. PubMed ID: 18799565
[No Abstract] [Full Text] [Related]
11. [How safe is our treatment with heparins? (interview by Maria Weiss)].
Lindhoff-Last E
MMW Fortschr Med; 2008 May; 150(22):7. PubMed ID: 18700259
[No Abstract] [Full Text] [Related]
12. The tainted heparin story: an update.
Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
[TBL] [Abstract][Full Text] [Related]
13. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008.
McMahon AW; Pratt RG; Hammad TA; Kozlowski S; Zhou E; Lu S; Kulick CG; Mallick T; Dal Pan G
Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):921-33. PubMed ID: 20661880
[TBL] [Abstract][Full Text] [Related]
14. [Contaminated heparins].
Monneret C
Ann Pharm Fr; 2008 Aug; 66(4):212-5. PubMed ID: 18847567
[TBL] [Abstract][Full Text] [Related]
15. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes.
Warkentin TE; Greinacher A
Expert Opin Drug Saf; 2009 Mar; 8(2):129-44. PubMed ID: 19309242
[TBL] [Abstract][Full Text] [Related]
16. Tainted heparin crisis tested FDA's investigative skills.
Lavine G
Am J Health Syst Pharm; 2009 Feb; 66(3):210-1. PubMed ID: 19179633
[No Abstract] [Full Text] [Related]
17. Lessons learned from the contamination of heparin.
Liu H; Zhang Z; Linhardt RJ
Nat Prod Rep; 2009 Mar; 26(3):313-21. PubMed ID: 19240943
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
[TBL] [Abstract][Full Text] [Related]
19. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
[TBL] [Abstract][Full Text] [Related]
20. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.
Adam A; Montpas N; Keire D; Désormeaux A; Brown NJ; Marceau F; Westenberger B
Biomaterials; 2010 Aug; 31(22):5741-8. PubMed ID: 20427081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
